Kornimate/medical-research-clean huggingface dataset:
psychological wellbeing in chronic fatigue syndrome

Conditions: Chronic Fatigue Syndrome

Summary: objectives: chronic fatigue syndrome (cfs) is a medically unexplained condition characterized by severe and disabling fatigue. to date much research has focused on finding out whether cfs is caused by mainly physical or psychological factors. perhaps as a result of this, few studies have examined the relationship between cfs and quality of life, in particular, more positive aspects of mental health, such as an individual's sense of purpose, autonomy and close relationships. this study will address these limitations by examining ryff's (1989) six domains of psychological well-being (pwb), and other aspects of well-being including positive emotions, in cfs. it will also examine the relationship between measures of symptomology, emotional distress and pwb. method: this is a cross-sectional, questionnaire-based study with a clinical sample of adults with cfs. participants will complete valid measures of well-being and symptomology. results: we expect to find that compared to general population norms, individuals with cfs score lower on measures of pwb. secondly, we expect pwb dimensions will be related to symptom measures. there are however, no grounds for making strong predictions. implications: this study will advance our understanding of quality of life in cfs. clinically, it has the potential to enrich and inform therapeutic interventions.


Eligibility criteria:
inclusion criteria: 1. chronic fatigue syndrome as defined by nice (2007). 2. aged 18 or over 3. english speaking exclusion criteria: 1. insufficient english language skills to participate without the use of an interpreter. 2. insufficient ability to read and write independently. 3. incapacity to consent to the study as defined by the mental capacity act (2005).
treatment of muscle injuries with physium therapy.

Conditions: Injuries; Muscle, Nontraumatic

Summary: muscle injuries are currently particularly frequent among people who participate in sports. the diagnosis is easily made with an ultrasound study and shear wave elastography.

patients of the experimental group, after diagnosis by ultrasound and shear wave elastography , will receive five sessions of physium therapy at 80 millibars during one month. the measurements of the variables visual analog scale, joint mobility through the double inclinometer device, elasticity and tissue vascularization through the ultrasound, quality of life through sf-12 questionnaire and pressure algometry will be made before, after, month and three months after the end of treatment.

Eligibility criteria:
inclusion criteria: * patients of both sexes, aged between 20 and 60 years, in an active state of pain and diagnosed with muscle breakdown. exclusion criteria: * patients who are pregnant, have pacemakers and surgically operated in the area to be treated.

Keywords: manual therapy massage physium pain range of motion quality of life muscle injuries
bilateral ultrasound guided superficial parasternal intercostal plane block versus erector spinae plane block

Conditions: CHD - Congenital Heart Disease

Summary: group (a): this group will receive fentanyl infusion at a dose of (0.5μg/kg/h) all through the whole operation plus ultrasound guided bilateral superficial parasternal intercostal plane block which will be done by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side3. group (b): this group will receive fentanyl infusion at a dose of (0.5μg/kg/h) all through the whole operation plus ultrasound guided bilateral espb which will be done by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side .

preoperative assessment premedication monitoring general anesthesia induction arterial and venous cannulation fentanyl infusion giving block according to the group intra operative recording of hemodynamics post operative pain assessment

Eligibility criteria:
inclusion criteria: * rachs-1: categories 1, 2 and 3 * patients undergoing corrective cardiac surgeries with midline sternotomy incision. * redo surgeries. exclusion criteria: * patients whose parents or legal guardians refuse to participate. * preoperative mechanical ventilation. * preoperative inotropic drug infusion. * coagulopathy. * allergy to any of the studied drugs. * severe pulmonary hypertension (\> 70 mmhg).

Keywords: chd regional anaesthesia pain management
optimization of interval-training in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: a single bout of interval-walking (iw) exercise is superior to energy-expenditure and time-duration matched continuous walking (cw) exercise upon improving glycemic control. the time spend with high-intensity (fast) walking is considered to be responsible for the improvements seen, whereas the time spend with low-intensity (slow) walking is considered less important. this study will assess if iw with maintained fast walking time duration but reduced total time duration (i.e. reduced slow walking time duration) is equally effective as iw with a normal time duration. subjects with type 2 diabetes will be included in a crossover, controlled study, where each subject will undergo three trials. trials will be identical except the following interventions: 1. sixty minutes of rest (con) 2. sixty minutes of classical interval walking (repeated cycles of 3 minutes of fast and 3 minutes of slow walking; iw-60) 3. fourty-five minutes of time-reduced interval walking (repeated cycles of 3 minutes of fast and 1.5 minutes of slow walking; iw-45). after the interventions subjects will undergo a standardized mixed meal tolerance test with assessment of glycemic control.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * bmi \> 25 exclusion criteria: * pregnancy * smoking * contraindication to increased levels of physical activity * eating disorder * insulin dependence

Keywords: glycemic control exercise interval training
association between radial artery intervention and development of neuropathy in the hand - a prospective study

Conditions: Ischemic Heart Disease; Nerve Injury; Carpal Tunnel Syndrome

Summary: evaluation of potential nerve damage after radial cag/pci.

prospective patients scheduled for radial cag/ pci will be enrolled in the study. prior to the procedure, sensory and motor nerve examination is performed at the wrists in both arms / hands. the examination is performed on both the median nerve and the ulnar nerve. each patient acts as their own control. the nerve test is repeated bilaterally 1 month after the procedure. this creates 2 groups, a and b. patients will be asked to complete 2 questionnaires in relation to hand and arm symptoms. the patients ability to perform certain activities before and after the cag/pci procedure are also addressed. in addition, a diagnostic tool (katz chart) will be completed, also before and after the cag/pci procedure. hypothesis: radial access is associated with an increased risk of pain and an increased incidence of nerve damage similar to the median nerve at the carpal tunnel or the ulnar nerve at the guyon's canal.

Eligibility criteria:
inclusion criteria: * the patient must be able to give informed consent exclusion criteria: * pregnancy * negative barbeau test

Keywords: transradial access ischemic heart disease hand dysfunction
cancer predisposition testing by family-based whole-genome sequencing (wgs) in every child with newly diagnosed cancer

Conditions: Neoplastic Syndromes, Hereditary; Cancer; Genetic Predisposition to Disease

Summary: assessment of the utility of family-based (trio) whole-genome sequencing for cancer predisposition testing in sequential newly diagnosed paediatric and adolescent cancer patients

cancer predisposition syndromes (cps), caused by germline mutations in cancer predisposition genes (cpg) are heritable disorders associated with an increased risk of developing certain types of cancer. knowledge of cpg will advance the understanding of tumorigenesis, improve patient care, and facilitate genetic counselling of patients and families. but the prevalence of cps in australian children with cancer and the psychosocial impact of germline sequencing to identify cpg have not been studied. the clinical benefit of family-based wgs in every new child with cancer compared with conventional predictive factors is currently unknown. by testing every child with newly diagnosed cancer the aim is to determine the utility of this approach and its impact on participants and families. the principal objective of the proposed multicentre prospective study is establish the clinical benefit and utility of family-based wgs to identify underlying cps in every newly diagnosed child with cancer.

Eligibility criteria:
* new diagnosis of malignancy * age ≤ 21 years * written informed consent psychosocial component: * participants (≥ 12 years) * parent/caregiver(s) of participants * healthcare professionals involved in the care of patients enrolled in the study

Keywords: germ-line mutation disease susceptibility child pediatrics genomics next generation sequencing risk
phase iii, randomized, double-blind, placebo-controlled, trial of linaclotide administered to patients with chronic constipation

Conditions: Chronic Constipation

Summary: the objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (cc). the primary efficacy parameter is the percentage of patients in each treatment group that meet the protocol definition for complete spontaneous bowel movement (csbm) overall responder


Eligibility criteria:
inclusion criteria: * patient has completed a colonoscopy according to the aga criteria, with no clinically significant findings * patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ecg, or clinical laboratory tests * patient meets protocol criteria for cc: reports \ 25% of bms * patient demonstrates continued chronic constipation through pretreatment period * patient is compliant with ivrs exclusion criteria: * patient has history of loose or watery stools * patient has symptoms of or been diagnosed with irritable bowel syndrome (ibs) * patient has a structural abnormality of the gastrointestinal (gi) tract or a disease or condition that can affect gi motility * patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

Keywords: constipation chronic constipation linaclotide
retrospective study on participants with short bowel syndrome and chronic intestinal failure that underwent transplantation in brazil

Conditions: Short Bowel Syndrome (SBS)

Summary: the main aim of this study is to capture management and treatment outcome data in participants with short bowel syndrome and chronic intestinal failure (sbs-if) that underwent intestinal transplantation in brazil. this study is about collecting data available in the participant's medical record and will also describe the demographic and clinical characteristics of these participants. no medication will be provided to participants in this study. clinical data will be collected from a period up to 10 years before the day of the intestinal transplantation. no clinic visits will be required as part of participation in this study.


Eligibility criteria:
inclusion criteria * participants with a diagnosis of sbs-if, who underwent intestinal transplantation between april 2011 to april 2021. * participants who have signed the informed consent form (or his/her legal representative). for deceased participants or those with lost to follow-up, an informed consent form (icf) waiver is acceptable.

Keywords: chronic intestinal failure
long term follow-up in patients with stage 0-iiic breast cancer

Conditions: Breast Cancer

Summary: this trial studies long term follow-up care in patients with stage 0-iiic breast cancer. collecting feedback from breast cancer patients may help researchers to define comprehensive long term follow-up care for breast cancer survivors, better understand health-related quality of life and long-term complications in breast cancer survivors, and to increase the knowledge of the mechanisms by which a patient's own immune system attempts to combat breast cancer, and what factors may make this response more successful.

primary objectives: i. to provide comprehensive care to breast cancer survivors diagnosed with stage 0 to iiic, who received at least part of their treatment at city of hope. ii. to use the information obtained from follow-up of breast cancer survivors to describe the magnitude of risk and associated risk factors. iii. to use the information gained from follow-up of breast cancer survivors to describe health-related quality of life (hrql) concerns in breast cancer survivors and identify those at highest risk. outline: patients undergo long term follow-up and complete questionnaires.

Eligibility criteria:
inclusion criteria: * diagnosis of breast cancer, stage 0-iiic * partial or entire treatment at city of hope * must be registered before adjuvant therapy and ideally before definitive local therapy exclusion criteria: * stage iv breast cancer * recurrent breast cancer * prior cancers, chemotherapy or radiation \* (note: subjects who develop locoregional or systemic recurrence while enrolled on this protocol will be withdrawn, and will continue their care with their primary oncology providers only)
survey study for velaglucerase alfa (vpriv) in japan

Conditions: Gaucher Disease

Summary: the objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (vpriv) in participants with gaucher disease who are new to therapy or have been switched from another therapeutic agent for gaucher disease.


Eligibility criteria:
inclusion criteria: * male or female participants with a confirmed diagnosis of gaucher disease * participants who are either naïve to treatment or participants that have been treated with another therapeutic agent for gaucher disease * participants who start vpriv treatment or transition from vpriv clinical studies during the enrollment period exclusion criteria: -
discontinuation of hypomethylating agent and venetoclax in patients with aml mrd

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this research study is to see if people whose acute myeloid leukemia (aml) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood that their aml will return.


Eligibility criteria:
inclusion criteria: * adults 18 years of age or older at the time of obtaining informed consent. * diagnosed with acute myeloid leukemia (aml) (non-m3) as defined by 2016 world health organization (who) * eastern cooperative group (ecog) performance status score ≤ 2 * currently on frontline therapy with hma (azacitidine or decitabine)/ven and achieved complete remission (cr)/complete remission with incomplete marrow recovery (cri) with mrd negativity defined as \< 0.1% by multiparameter flow cytometry (mfc) * within 12 months of starting hma (azacitidine or decitabine)/ven * ineligible for or declined allogeneic hematopoietic cell transplantation (hct) * ability to understand and the willingness to sign a written informed consent document * must agree to adhere to the study visit schedule and other protocol requirements * patients must be able to provide adequate bone marrow (bm) aspirate and biopsy specimens for histopathological and measurable residual disease analysis during the screening procedure exclusion criteria: * use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of aml within 28 days, or 5 half-lives, at the start of the study. only patients who are receiving frontline hma (azacitidine or decitabine)/ven are potentially eligible, but if they had received a course of hydroxyurea prior to achieving cr/cri, this is allowed. * any serious medical condition or uncontrolled current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or will place the subject at unacceptable risk if he/she participates in the study. controlled infections or other medical conditions on long-term therapy is allowed. * patients who harbored tp53 mutation at diagnosis * aml with extramedullary involvement including central nervous system (cns) involvement, myeloid sarcoma, and leukemia cutis requiring directed therapy at the time of enrollment. * patient is pregnant.

Keywords: aml
probiotics, immune function, and the brain in alcohol consumers

Conditions: Alcohol; Use, Problem

Summary: this pilot project is a brief, open-label clinical trial of probiotics as an intervention in heavy drinkers. heavy drinkers who do not yet show significant signs of liver disease may stand to benefit from probiotics, but no clinical trials to date have addressed this population. this study will recruit heavy drinkers to complete an open-label within-subjects trial. the study will investigate effects of probiotics on specific biomarkers in healthy heavy drinkers who currently are not seeking to change their alcohol use (i.e., are non-treatment-seeking).

this pilot project is a brief, open-label clinical trial of probiotics as an intervention to reduce systemic and neural inflammation in heavy drinkers. heavy drinkers who do not yet show significant signs of liver disease also may stand to benefit from probiotics, but no clinical trials to date have addressed this population. this study will recruit 15 non-treatment-seeking heavy drinkers to complete an open-label within-subjects trial. aim 1 is to demonstrate proof-of-concept for beneficial effects of probiotic use on inflammatory processes. aim 2 is to examine effects of probiotic use on brain metabolites correlated with neuroinflammation using magnetic resonance spectroscopy. aim 3 is to gather preliminary data on acceptability and feasibility of the probiotic intervention in non-treatment-seeking heavy drinkers.

Eligibility criteria:
inclusion criteria: * 18-64 years old; * able to speak and read english well enough to complete study procedures; * meets niaaa guidelines for heavy drinking in the past 30 days. exclusion criteria: * chronic disease requiring daily use of medication; * seeking or receiving treatment for alcohol/drug use, with exception of smoking cessation; * self-reported history of liver disease; * antibiotic or probiotic use in past 1 month; * positive urine drug test; * history of fainting, weakness, infection, excessive bruising, or extreme distress from blood draw; * safety contraindication for mri (e.g., ferromagnetic implant in the body, claustrophobia); * head trauma with loss of consciousness \>10 min; * pregnant, breastfeeding, or not using effective birth control; * unable to complete the study visits due to time or scheduling constraints; * weight \<110 lbs. * conditions of immunodeficiency, such as hiv infection, primary immune deficiency, or taking immune-suppressant medications.

Keywords: alcohol use probiotics heavy drinking brain immune function
evaluation of the effect of metformin on metastatic breast cancer as adjuvant treatment

Conditions: Metastatic Breast Cancer

Summary: this study aims to determine the effect of metformin along with standard cancer treatment, and its effect on the prognosis of the metastatic breast in non-diabetic patients.

the role of metformin when combined with traditional metastatic breast cancer treatment in non-diabetic patients compared to diabetic patients who are not using metformin. in this randomized control study, there will be a demonstration either it is effective to suppress tumor burden or not through normal screening for tumor.

Eligibility criteria:
inclusion criteria: * the non-diabetic patients will be included in the study if they meet the following criteria: 1. confirmed metastatic breast cancer (iv stage) radiologically or by clinical evaluation receiving chemotherapy 2. age between 18- 70 years. 3. life expectancy at least 6 months exclusion criteria: * the patients will be excluded from the study if they have the following criteria: 1. bad prognosis disease: criteria defined as the following * if patient \>70 years * if patient has bad site metastasis (brain) 2. hypersensitivity for metformin: if happened patient will be treated as following • pheniramine maleate 3 times daily for 7 days and tablet dexamethasone 1mg daily in 2 divided doses for 5 days \[16\]. 3. any condition associated with increased risk of metformin-associated lactic acidosis (e.g., congestive heart failure defined as new york heart association {nyha} class iii or iv functional status; the history of acidosis of any type, severe infections, kidney or liver disease, respiratory disease, seizures . 4. diabetic patients.

Keywords: metformin non metastatic breast cancer non-diabetic
subjective perception of ocular prosthesis wear

Conditions: Anophthalmos, Unilateral; Prosthesis User

Summary: the loss of an eye, whether congenital or acquired, is a severe psychological trauma with negative impact on the quality of life of the patient. while rehabilitation with a customized ocular prosthesis anatomically restores the facial appearance, the final outcome is largely determined by the subjective satisfaction of the patient. by investigating the level of subjective perception, the quality of care can be improved.


Eligibility criteria:
inclusion criteria: * acquired anophthalmia * informed consent * ocular prosthesis wear for minimum of 2 years exclusion criteria: * congenital anophthalmia * microphthalmia
electrical stimulation and expression of vegf and no in diabetic foot ulcer

Conditions: Diabetic Foot Ulcer

Summary: this study aimed to investigate the effect of low intensity cathodal direct current on the release of plasma vascular endothelial growth factor (vegf) and nitric oxide (no) in diabetic foot ulceration.

twenty type 2 diabetic patients with foot ulceration and 13 age-matched healthy subjects were enrolled. patients were randomly assigned to electrical stimulation (es, n=10) or sham es (placebo, n=10) groups. es group received cathodal direct current for 1 h/day, 3 days/week, for 4 weeks (12 sessions). blood sample was collected for vegf and no measurement in the first and last treatment sessions before and after intervention. wound surface area (wsa) and skin temperature were measured at 1st, 6th, and 12th session.

Eligibility criteria:
inclusion criteria: * wagner classification dfu 2; * age 40-60 years; * mild to moderate diabetic neuropathy; * abi\>0.7 * wound surface area\>1.5cm2 exclusion criteria: * fracture in a lower limb, * a severe infection, * a malignancy, * kidney failure, * skin diseases, * osteomyelitis, * pregnancy,
decompression and drainage seton for treatment of high horseshoe anal fistula

Conditions: Anal Fistula

Summary: patients with high horseshoe anal fistula will be randomized to one of two equal group: treatment group will have decompression and drainage seton and control group will undergo cutting seton.


Eligibility criteria:
inclusion criteria: * patients suffering from high horseshoe anal fistula exclusion criteria: * specific cause of fistula e.g. crohn's disease. * previous anorectal surgery. * patients with malignant tumors or mental illness or other reasons unable to cooperate with the treatment. * patients with serious primary diseases such as tumor, malnutrition, endocrine and hematopoietic system.